ReShape Lifesciences (US:RSLS)2025-06-17 08:37Merger and Company Overview - Vyome Therapeutics intends to list on Nasdaq via reverse merger with $RSLS under the ticker $HIND[7] - The merger valuation is $120 million[42] - The company is building a 3-pillared healthcare platform in the US-India innovation corridor[7, 11] Market Opportunity and Assets - The immuno-inflammatory market is expected to reach $125 billion+ by 2028[8] - Vyome's assets include treatments for Malignant Fungating Wound (MFW), Uveitis, and Inflammatory acne[19] - The market size for Malignant Fungating Wound is estimated at $2.5 billion by 2032[19] - The total global acne market is forecasted to grow to $11.6 billion by 2028, with inflammatory acne comprising over 50% of the acne market[19] MFW Program - The MFW market represents a ~$1 billion/year unmet need with no approved drug[21, 26] - New data released in December 2024 shows a 75%+ reduction in odor and 50%+ increase in quality of life with Vyome's drug for MFW[27] Valuation and Comparables - Public comparables in the Inflammation & Immunology Market have an average market cap of $419 million[47] - Precedent M&A comparables in the Acquired Inflammation & Immunology Market have an average market cap of $2.8 billion and a transaction price of $482 million[51]